Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

NeoStem Subsidiary Receives SFDA Approval for Antibiotic

publication date: Apr 6, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
NeoStem, Inc. reported that its China subsidiary, Suzhou Erye Pharma, was granted SFDA approval to produce cloxacillin sodium API, a generic anti-infective. Because it is included in China’s National Medical Reimbursement Insurance List, Cloxacillin sodium is eligible for reimbursement by the government's healthcare programs. More details...

Stock Symbol: (NYSE Amex: NBS)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors